Abdurrahman Tufan: Combination Targeted Therapy in Refractory Systemic Autoinflammatory Diseases
Abdurrahman Tufan, Clinical Consultant and Instructor at Gazi University, shared a post on LinkedIn:
“I’m very pleased to share our new publication in Seminars in Arthritis and Rheumatism:
‘Biologic biologic and biologic JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases.’
Our findings demonstrate the potential of combination targeted therapy to achieve sustained disease control in selected patients with severe and refractory systemic autoinflammatory diseases (SAIDs), including those with persistent inflammation and limited therapeutic options.
In this retrospective longitudinal cohort from the NIH Inflammatory Disease Section, we evaluated advanced combination therapy (ACT) using biologics and or JAK inhibitors in patients with difficult to treat SAIDs.
Among 38 patients, 65 ACT regimens were administered. Following multiple treatment trials:
- 55.3 percent achieved a complete response
- 31.6 percent achieved a partial response
- 68 percent of patients remained on combination therapy at final follow up
- Median duration of ACT was 5 years (range 11 to 186 months)
I am very grateful to all of my co authors and colleagues who contributed to this study, and especially to Daniel L. Kastner, whose mentorship and vision have profoundly influenced our work in autoinflammatory diseases.”
Stay updated with Hemostasis Today.
-
Sep 19, 2026, 03:15Paulus Kirchhof: Europe’s Safe Hearts Plan to Reduce Cardiovascular Mortality
-
Sep 19, 2026, 03:10James Smith: Brain Training and Exercise for Cognitive Recovery After Stroke
-
Sep 19, 2026, 03:03Lesley Van Wyk: ASH Releases New Iron Deficiency Diagnosis Guidelines
-
Sep 19, 2026, 02:53Francisco Chacón-Lozsán: Acute Ischemic Stroke in 2026 – Expanding the Treatment Window
-
Sep 19, 2026, 01:53Thomas Dayspring: Understanding Genome and Lipid Interactions in Lipidology
-
Sep 19, 2026, 01:44Patrick James Lynch: Mother of a Thousand Sons Premieres at BDC 2026
-
Sep 19, 2026, 01:41Genetic Fate Mapping Reveals Endothelial Cells During Venous Thrombus Resolution – RPTH Journal
-
Sep 19, 2026, 01:39Mostafa Hammam: Three Different Platelet Defects – One Common Symptom
-
Sep 19, 2026, 01:38Jeff Sternlicht: A Heart Attack Should Not Be the Starting Line